{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:20:16Z","timestamp":1774930816545,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Community-acquired Pneumonia (CAP) guidelines generally recommend to admit patients with moderate-to-severe CAP and start\u00a0treatment with intravenous antibiotics. This study aims to explore the clinical outcomes of oral antibiotics in patients with moderate-to-severe CAP. We performed a nested cohort study of an observational study including all adult patients presenting to the emergency department of the Haga Teaching Hospital, the Netherlands, between April 2019 and May 2020, who had a blood culture drawn. We conducted propensity score matching with logistic and linear regression analysis to compare patients with moderate-to-severe CAP (Pneumonia Severity Index class III\u2013V) treated with oral antibiotics to patients treated with intravenous antibiotics. Outcomes were 30-day mortality, intensive care unit admission, readmission, length of stay (LOS) and length of antibiotic treatment. Of the original 314 patients, 71 orally treated patients were matched with 102 intravenously treated patients. The mean age was 73 years and 58% were male. We found no significant differences in outcomes between the oral and intravenous group, except for an increased LOS of\u2009+\u20092.6\u00a0days (95% confidence interval 1.2\u20134.0, <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.001) in those treated intravenously. We conclude that oral antibiotics might be a safe and effective treatment for moderate-to-severe CAP for selected patients based on the clinical judgement of the attending physician.<\/jats:p>","DOI":"10.1038\/s41598-024-59026-2","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T07:02:21Z","timestamp":1712646141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral versus intravenous antibiotic treatment of moderate-to-severe community-acquired pneumonia: a propensity score matched study"],"prefix":"10.1038","volume":"14","author":[{"given":"Anna G.","family":"Kaal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick","family":"Roos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rianne M. C.","family":"Pepping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna M. W.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten O.","family":"van Aken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewout W.","family":"Steyerberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattijs E.","family":"Numans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees","family":"van Nieuwkoop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"59026_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/B978-0-7020-6285-8.00028-9","volume":"2017","author":"RG Wunderink","year":"2016","unstructured":"Wunderink, R. G. Community-acquired pneumonia. Infect. Dis. 2017, 251\u2013257. https:\/\/doi.org\/10.1016\/B978-0-7020-6285-8.00028-9 (2016).","journal-title":"Infect. Dis."},{"issue":"4","key":"59026_CR2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.vaccine.2019.10.101","volume":"38","author":"JM McLaughlin","year":"2020","unstructured":"McLaughlin, J. M., Khan, F. L., Thoburn, E. A., Isturiz, R. E. & Swerdlow, D. L. Rates of hospitalization for community-acquired pneumonia among US adults: A systematic review. Vaccine 38(4), 741\u2013751. https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.101 (2020).","journal-title":"Vaccine"},{"issue":"1","key":"59026_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/thx.2009.129502","volume":"67","author":"T Welte","year":"2012","unstructured":"Welte, T., Torres, A. & Nathwani, D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67(1), 71\u201379. https:\/\/doi.org\/10.1136\/thx.2009.129502 (2012).","journal-title":"Thorax"},{"issue":"1","key":"59026_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/14760584.2023.2261785","volume":"22","author":"E Tsoumani","year":"2023","unstructured":"Tsoumani, E., Carter, J. A., Salomonsson, S., Stephens, J. M. & Bencina, G. Clinical, economic, and humanistic burden of community acquired pneumonia in Europe: A systematic literature review. Expert Rev. Vaccines 22(1), 876\u2013884. https:\/\/doi.org\/10.1080\/14760584.2023.2261785 (2023).","journal-title":"Expert Rev. Vaccines"},{"key":"59026_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.rmed.2016.10.015","volume":"121","author":"M Kolditz","year":"2016","unstructured":"Kolditz, M. et al. Burden and risk factors of ambulatory or hospitalized CAP: A population based cohort study. Respir. Med. 121, 32\u201338. https:\/\/doi.org\/10.1016\/j.rmed.2016.10.015 (2016).","journal-title":"Respir. Med."},{"issue":"7","key":"59026_CR6","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay, J. P. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am. J. Respir. Crit. Care Med. 200(7), e45\u2013e67. https:\/\/doi.org\/10.1164\/rccm.201908-1581ST (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl 3","key":"59026_CR7","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","volume":"64","author":"WS Lim","year":"2009","unstructured":"Lim, W. S. et al. Pneumonia guidelines committee of the BTS standards of care committee. BTS guidelines for the management of community acquired pneumonia in adults: Update 2009. Thorax 64(Suppl 3), iii1\u2013iii55. https:\/\/doi.org\/10.1136\/thx.2009.121434 (2009).","journal-title":"Thorax"},{"key":"59026_CR8","unstructured":"National Institute for Health and Care Excellence (NICE). Pneumonia in Adults: Diagnosis and Management (2022)."},{"key":"59026_CR9","unstructured":"National Institute for Health and Care Excellence (NICE). Pneumonia (Community-Acquired): Antimicrobial Prescribing (2019)."},{"issue":"1","key":"59026_CR10","first-page":"4","volume":"76","author":"WJ Wiersinga","year":"2018","unstructured":"Wiersinga, W. J. et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch working party on antibiotic policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth J. Med. 76(1), 4\u201313 (2018).","journal-title":"Neth J. Med."},{"issue":"4","key":"59026_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJM199701233360402","volume":"336","author":"MJ Fine","year":"1997","unstructured":"Fine, M. J. et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336(4), 243\u2013250. https:\/\/doi.org\/10.1056\/NEJM199701233360402 (1997).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"59026_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377.PMID:12728155","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim, W. S. et al. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 58(5), 377\u2013382. https:\/\/doi.org\/10.1136\/thorax.58.5.377.PMID:12728155 (2003).","journal-title":"Thorax"},{"key":"59026_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jgar.2022.12.010","volume":"32","author":"GL Teng","year":"2023","unstructured":"Teng, G. L., Chi, J. Y., Zhang, H. M., Li, X. P. & Jin, F. Oral vs. parenteral antibiotic therapy in adult patients with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. J. Glob. Antimicrob. Resist. 32, 88\u201397. https:\/\/doi.org\/10.1016\/j.jgar.2022.12.010 (2023).","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"2","key":"59026_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s10096-003-1060-x","volume":"23","author":"V Erard","year":"2004","unstructured":"Erard, V. et al. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 23(2), 82\u201388. https:\/\/doi.org\/10.1007\/s10096-003-1060-x (2004).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"4","key":"59026_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1378\/chest.127.4.1260","volume":"127","author":"TJ Marrie","year":"2005","unstructured":"Marrie, T. J. & Wu, L. Factors influencing in-hospital mortality in community-acquired pneumonia: A prospective study of patients not initially admitted to the ICU. Chest 127(4), 1260\u20131270. https:\/\/doi.org\/10.1378\/chest.127.4.1260 (2005).","journal-title":"Chest"},{"issue":"4","key":"59026_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1155\/2007\/451417","volume":"14","author":"TJ Marrie","year":"2007","unstructured":"Marrie, T. J. & Huang, J. Q. Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. Can. Respir. J. 14(4), 212\u2013216. https:\/\/doi.org\/10.1155\/2007\/451417 (2007).","journal-title":"Can. Respir. J."},{"issue":"7","key":"59026_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cmi.2019.11.028","volume":"26","author":"A Huttner","year":"2020","unstructured":"Huttner, A. et al. Oral amoxicillin and amoxicillin-clavulanic acid: Properties, indications and usage. Clin. Microbiol. Infect. 26(7), 871\u2013879. https:\/\/doi.org\/10.1016\/j.cmi.2019.11.028 (2020).","journal-title":"Clin. Microbiol. Infect."},{"issue":"4","key":"59026_CR18","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/AAC.04659-14","volume":"59","author":"K \u00d6brink-Hansen","year":"2015","unstructured":"\u00d6brink-Hansen, K. et al. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. Antimicrob. Agents Chemother. 59(4), 2398\u20132404. https:\/\/doi.org\/10.1128\/AAC.04659-14 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"59026_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jac\/dkac401","volume":"78","author":"AK Van Den Broek","year":"2023","unstructured":"Van Den Broek, A. K. et al. The effect of the acute phase of infection on absorption of and exposure to orally administered antibiotics in non-critically ill, hospitalized patients. J Antimicrob Chemother. 78(2), 389\u2013396. https:\/\/doi.org\/10.1093\/jac\/dkac401 (2023).","journal-title":"J Antimicrob Chemother."},{"issue":"4","key":"59026_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/s0163-4453(80)92720-6","volume":"2","author":"SA Hill","year":"1980","unstructured":"Hill, S. A., Jones, K. H. & Lees, L. J. Pharmacokinetics of parenterally administered amoxycillin. J. Infect. 2(4), 320\u2013332. https:\/\/doi.org\/10.1016\/s0163-4453(80)92720-6 (1980).","journal-title":"J. Infect."},{"issue":"5817","key":"59026_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/bmj.3.5817.13","volume":"3","author":"R Sutherland","year":"1972","unstructured":"Sutherland, R., Croydon, E. A. & Rolinson, G. N. Amoxycillin: A new semi-synthetic penicillin. Br Med J. 3(5817), 13\u201316. https:\/\/doi.org\/10.1136\/bmj.3.5817.13 (1972).","journal-title":"Br Med J."},{"key":"59026_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.phrs.2018.07.005","volume":"134","author":"F de Velde","year":"2018","unstructured":"de Velde, F., Mouton, J. W., de Winter, B. C. M., van Gelder, T. & Koch, B. C. P. Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. Pharmacol. Res. 134, 280\u2013288. https:\/\/doi.org\/10.1016\/j.phrs.2018.07.005 (2018).","journal-title":"Pharmacol. Res."},{"issue":"5","key":"59026_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Developpment and validation. J. Chronic Dis. 40(5), 373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8 (1987).","journal-title":"J. Chronic Dis."},{"issue":"7872","key":"59026_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0140-6736(74)91639-0","volume":"2","author":"G Teasdale","year":"1974","unstructured":"Teasdale, G. & Jennett, B. Assessment of coma and impaired consciousness. A practical scale. Lancet 2(7872), 81\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(74)91639-0 (1974).","journal-title":"Lancet"},{"issue":"1","key":"59026_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mpr.329.PMID:21499542;PMCID:PMC3074241","volume":"20","author":"MJ Azur","year":"2011","unstructured":"Azur, M. J., Stuart, E. A., Frangakis, C. & Leaf, P. J. Multiple imputation by chained equations: What is it and how does it work?. Int. J. Methods Psychiatr. Res. 20(1), 40\u201349. https:\/\/doi.org\/10.1002\/mpr.329.PMID:21499542;PMCID:PMC3074241 (2011).","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"59026_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-77244-8","volume-title":"Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating","author":"EW Steyerberg","year":"2009","unstructured":"Steyerberg, E. W. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating (Springer, 2009)."},{"issue":"9","key":"59026_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.21037\/atm-20-3998","volume":"9","author":"QY Zhao","year":"2021","unstructured":"Zhao, Q. Y. et al. Propensity score matching with R: Conventional methods and new features. Ann. Transl. Med. 9(9), 812. https:\/\/doi.org\/10.21037\/atm-20-3998 (2021).","journal-title":"Ann. Transl. Med."},{"issue":"6","key":"59026_CR28","doi-asserted-by":"publisher","first-page":"e2218172","DOI":"10.1001\/jamanetworkopen.2022.18172","volume":"5","author":"E Dregmans","year":"2022","unstructured":"Dregmans, E. et al. Analysis of variation between diagnosis at admission vs discharge and clinical outcomes among adults with possible bacteremia. JAMA Netw. Open 5(6), e2218172. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.18172 (2022).","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"59026_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 315(8), 801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287 (2016).","journal-title":"JAMA."},{"issue":"2","key":"59026_CR30","doi-asserted-by":"publisher","first-page":"bjgpopen965","DOI":"10.3399\/bjgpopen17X100965","volume":"1","author":"FJ Loots","year":"2017","unstructured":"Loots, F. J. et al. Recognition of sepsis in primary care: A survey among GPs. BJGP Open 1(2), bjgpopen965. https:\/\/doi.org\/10.3399\/bjgpopen17X100965 (2017).","journal-title":"BJGP Open"},{"issue":"7580","key":"59026_CR31","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/bmj.38993.560984.BE","volume":"333","author":"JJ Oosterheert","year":"2006","unstructured":"Oosterheert, J. J. et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: Multicentre randomised trial. BMJ 333(7580), 1193. https:\/\/doi.org\/10.1136\/bmj.38993.560984.BE (2006).","journal-title":"BMJ"},{"issue":"1","key":"59026_CR32","doi-asserted-by":"publisher","first-page":"ofx014","DOI":"10.1093\/ofid\/ofx014","volume":"4","author":"AM Harris","year":"2017","unstructured":"Harris, A. M. et al. Influence of antibiotics on the detection of bacteria by culture-based and culture-independent diagnostic tests in patients hospitalized with community-acquired pneumonia. Open Forum Infect. Dis. 4(1), ofx014. https:\/\/doi.org\/10.1093\/ofid\/ofx014 (2017).","journal-title":"Open Forum Infect. Dis."},{"issue":"8","key":"59026_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1086\/533441","volume":"46","author":"PE Pertel","year":"2008","unstructured":"Pertel, P. E. et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin. Infect. Dis. 46(8), 1142\u20131151. https:\/\/doi.org\/10.1086\/533441 (2008).","journal-title":"Clin. Infect. Dis."},{"issue":"suppl_3","key":"59026_CR34","doi-asserted-by":"publisher","first-page":"S368","DOI":"10.1093\/cid\/cix101","volume":"64","author":"AJ Driscoll","year":"2017","unstructured":"Driscoll, A. J. et al. The effect of antibiotic exposure and specimen volume on the detection of bacterial pathogens in children with pneumonia. Clin. Infect. Dis. 64(suppl_3), S368\u2013S377. https:\/\/doi.org\/10.1093\/cid\/cix101 (2017).","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"59026_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jac\/dkl224","volume":"58","author":"KN Agwuh","year":"2006","unstructured":"Agwuh, K. N. & MacGowan, A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J. Antimicrob. Chemother. 58(2), 256\u2013265. https:\/\/doi.org\/10.1093\/jac\/dkl224 (2006).","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"59026_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/cid\/ciad196","volume":"77","author":"A Deshpande","year":"2023","unstructured":"Deshpande, A. et al. Intravenous to oral antibiotic switch therapy among patients hospitalized with community-acquired pneumonia. Clin. Infect. Dis. 77(2), 174\u2013185. https:\/\/doi.org\/10.1093\/cid\/ciad196 (2023).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"59026_CR37","doi-asserted-by":"publisher","first-page":"ofac706","DOI":"10.1093\/ofid\/ofac706","volume":"10","author":"K Davar","year":"2022","unstructured":"Davar, K. et al. Can the future of ID escape the inertial dogma of its past? The exemplars of shorter Is better and oral is the new IV. Open Forum Infect Dis. 10(1), ofac706. https:\/\/doi.org\/10.1093\/ofid\/ofac706 (2022).","journal-title":"Open Forum Infect Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59026-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59026-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59026-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T07:04:12Z","timestamp":1712646252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-59026-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["59026"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-59026-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author MN has an advisory role in the guidelines NAFLD\/NASH and GORD and served as an unpaid QQ member for the Dutch Academic General Practice Network. All other authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8271"}}